Filtered By:
Specialty: Drugs & Pharmacology
Cancer: Cancer
Drug: Coumadin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 4 results found since Jan 2013.
Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010 –2016
ConclusionsNearly 7 out of 10 patients with cancer and NVAF did not receive anticoagulation. Use of DOACs increased from 2010 to 2016, with a corresponding decline in warfarin use. DOACs are used less than warfarin among those at higher risk of stroke.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 6, 2022 Category: Drugs & Pharmacology Authors: Shirin Ardeshirrouhanifard,
Huijun An,
Ravi K. Goyal,
Mukaila A. Raji,
Jodi B. Segal,
G. Caleb Alexander,
Hemalkumar B. Mehta Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the united states, 2010 ‐2016
ConclusionsNearly 7 out of 10 patients with cancer and NVAF did not receive anticoagulation. Use of DOACs increased from 2010 to 2016, with a corresponding decline in warfarin use. DOACs are used less than warfarin among those at higher risk of stroke.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 3, 2022 Category: Drugs & Pharmacology Authors: Shirin Ardeshirrouhanifard,
Huijun An,
Ravi K. Goyal,
Mukaila A. Raji,
Jodi B. Segal,
G. Caleb Alexander,
Hemalkumar B. Mehta Tags: RESEARCH ARTICLE Source Type: research
Safety and efficacy of new oral anticoagulants compared to those of warfarin in AF patients with cancer: a meta-analysis of randomized clinical trials and observational studies
ConclusionOur meta-analysis confirms that NOACs are as safe and effective as warfarin and can be applied in the real world; this data can serve as a reference for clinical doctors for formulating treatment strategies.
Source: European Journal of Clinical Pharmacology - April 1, 2021 Category: Drugs & Pharmacology Source Type: research
Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication
ConclusionMost of the well-established risk factors were found to be significantly associated with bleeding events in our study. We additionally found that women had a lower incidence of bleeding. Potential biases are selection effects, residual confounding and unmeasured frailty.
Source: European Journal of Clinical Pharmacology - March 27, 2020 Category: Drugs & Pharmacology Source Type: research